Ultragenyx Pharmaceutical (RARE) Gross Profit (2018 - 2025)
Historic Gross Profit for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Q3 2025 value amounting to $131.9 million.
- Ultragenyx Pharmaceutical's Gross Profit rose 1136.88% to $131.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $534.0 million, marking a year-over-year increase of 1845.12%. This contributed to the annual value of $483.5 million for FY2024, which is 2428.08% up from last year.
- According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Gross Profit is $131.9 million, which was up 1136.88% from $143.5 million recorded in Q2 2025.
- Ultragenyx Pharmaceutical's 5-year Gross Profit high stood at $148.0 million for Q4 2024, and its period low was $73.8 million during Q1 2022.
- Its 5-year average for Gross Profit is $101.5 million, with a median of $94.2 million in 2021.
- Per our database at Business Quant, Ultragenyx Pharmaceutical's Gross Profit skyrocketed by 18716.39% in 2021 and then crashed by 2162.47% in 2022.
- Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Gross Profit stood at $79.9 million in 2021, then rose by 22.72% to $98.0 million in 2022, then grew by 17.66% to $115.3 million in 2023, then grew by 28.3% to $148.0 million in 2024, then dropped by 10.84% to $131.9 million in 2025.
- Its Gross Profit was $131.9 million in Q3 2025, compared to $143.5 million in Q2 2025 and $110.6 million in Q1 2025.